Tyrosine kinase inhibitors for the treatment of acute myeloid leukemia: Delineation of anti-leukemic mechanisms of action

Biochemical Pharmacology

Volumn 82, Issue 10, 2011, Pages 1457-1466

  Lainey, Elodie ^a,b   Thépot, Sylvain ^a,b   Bouteloup, Cyrielle ^a,d   Sébert, Marie ^a,b   Ads, Lionel ^a,d   Tailler, Maximilien ^a,b,c   Gardin, Claude ^d   De Botton, Stéphane ^c   Baruchel, André ^e   Fenaux, Pierre ^a,b,c,d   Kroemer, Guido ^a,c,f,g,h   Boehrer, Simone ^a,d  

^a Institut Gustave Roussy   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d AVICENNE HOSPITAL   (France)

^e HÔPITAL ROBERT DEBRÉ   (France)

^f CENTRE DE RECHERCHE DES CORDELIERS   (France)

^g HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^h UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Apoptosis; Differentiation; Epidermal growth factor receptor; Erlotinib; Lapatinib; Tyrosine kinases

Indexed keywords

DASATINIB; ERLOTINIB; LAPATINIB; SORAFENIB; PROTEIN TYROSINE KINASE INHIBITOR;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL VIABILITY; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN CELL; LEUKEMIA CELL; MYELOBLAST; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; ADULT; AGED; DRUG MECHANISM; FEMALE; MALE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; LEUKOCYTES; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROTEIN-TYROSINE KINASES;

EID: 80054679819     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2011.05.011     Document Type: Conference Paper

References (33)

1. D.G. Gilliland, C.T. Jordan, and C.A. Felix The molecular basis of leukemia Hematol Am Soc Hematol Educ Prog 2004 80 97
2. D. Grimwade, H. Walker, F. Oliver, K. Wheatley, C. Harrison, and G. Harrison The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties Blood 92 7 1998 2322 2333 (Pubitemid 28452973)
3. D. Grimwade The clinical significance of cytogenetic abnormalities in acute myeloid leukaemia Best Pract Res Clin Haematol 14 3 2001 497 529 (Pubitemid 33019748)
4. D. Grimwade, H. Walker, G. Harrison, F. Oliver, S. Chatters, and C.J. Harrison The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial Blood 98 5 2001 1312 1320
5. D. Grimwade, A. Moorman, R. Hills, K. Wheatley, H. Walker, and G. Harrison Impact of karyotype on treatment outcome in acute myeloid leukemia Ann Hematol 83 Suppl 1 2004 S45 S48
6. M.L. Slovak, K.J. Kopecky, P.A. Cassileth, D.H. Harrington, K.S. Theil, and A. Mohamed Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study Blood 96 13 2000 4075 4083
7. D.G. Gilliland, and J.D. Griffin The roles of FLT3 in hematopoiesis and leukemia Blood 100 5 2002 1532 1542 (Pubitemid 34925124)
8. N.P. Shah, C. Tran, F.Y. Lee, P. Chen, D. Norris, and C.L. Sawyers Overriding imatinib resistance with a novel ABL kinase inhibitor Science 305 2004 399 401 (Pubitemid 38938156)
9. B.S. Guerrouahen, M. Futami, C. Vaklavas, J. Kanerva, Z.L. Whichard, and K. Nwawka Dasatinib inhibits the growth of molecularly heterogeneous myeloid leukemias Clin Cancer Res 16 February (4) 2010 1149 1158
10. K. Stegmaier, S.M. Corsello, K.N. Ross, J.S. Wong, D.J. Deangelo, and T.R. Golub Gefitinib induces myeloid differentiation of acute myeloid leukemia Blood 106 8 2005 2841 2848 (Pubitemid 41510762)
11. G. Chan, and M. Pilichowska Complete remission in a patient with acute myelogenous leukemia treated with erlotinib for non small-cell lung cancer Blood 110 3 2007 1079 1080 (Pubitemid 47267456)
12. S. Boehrer, L. Ades, T. Braun, L. Galluzzi, J. Grosjean, and C. Fabre Erlotinib exhibits anti-neoplastic off-target effects in AML and MDS: a preclinical study Blood 111 February (4) 2008 2170 2180 (Pubitemid 351451531)
13. V. Pitini, C. Arrigo, and G. Altavilla Erlotinib in a patient with acute myelogenous leukemia and concomitant non-small-cell lung cancer J Clin Oncol 26 July (21) 2008 3645 3646
14. E. Lindhagen, A. Eriksson, M. Wickström, K. Danielsson, B. Grundmark, and R. Henriksson Significant cytotoxic activity in vitro of the EGFR tyrosine kinase inhibitor gefitinib in acute myeloblastic leukaemia Eur J Haematol 81 November (5) 2008 344 353
15. R.H. Alvarez, V. Valero, and G.N. Hortobagyi Emerging targeted therapies for breast cancer J Clin Oncol 28 July (20) 2010 3366 3379
16. N. Zamzami, P. Marchetti, M. Castedo, C. Zanin, J.L. Vayssire, and P.X. Petit Reduction in mitochondrial potential constitutes an early irreversible step of programmed lymphocyte death in vivo J Exp Med 181 May (5) 1995 1661 1672
17. D. Métivier, B. Dallaporta, N. Zamzami, N. Larochette, S.A. Susin, and I. Marzo Cytofluorometric detection of mitochondrial alterations in early CD95/Fas/APO-1-triggered apoptosis of Jurkat T lymphoma cells. Comparison of seven mitochondrion-specific fluorochromes Immunol Lett 61 April (2-3) 1998 157 163 (Pubitemid 28260991)
18. M. Castedo, K. Ferri, T. Roumier, D. Metivier, N. Zamzami, and G. Kroemer Quantitation of mitochondrial alterations associated with apoptosis J Immunol Methods 265 1-2 2002 39 47 (Pubitemid 34628803)
19. L. Galluzzi, N. Zamzami, T. de La Motte Rouge, C. Lemaire, C. Brenner, and G. Kroemer Methods for the assessment of mitochondrial membrane permeabilization in apoptosis Apoptosis 12 5 2007 803 813 (Pubitemid 46653289)
20. T. Hirsch, I. Marzo, and G. Kroemer Role of the mitochondrial permeability transition pore in apoptosis Biosci Rep 17 February (1) 1997 67 76 (Pubitemid 27267593)
21. D.R. Green, and G. Kroemer Pharmacological manipulation of cell death: clinical applications in sight? J Clin Invest 115 October (10) 2005 2610 2617 (Pubitemid 41434383)
22. K.F. Ferri, and G. Kroemer Mitochondria - the suicide organelles Bioessays 23 February (2) 2001 111 115 (Pubitemid 32116642)
23. J. Kohroki, N. Muto, T. Tanaka, N. Itoh, A. Inada, and K. Tanaka Induction of differentiation and apoptosis by dithizone in human myeloid leukemia cell lines Leuk Res 22 May (5) 1998 405 412 (Pubitemid 28279126)
24. D. Nowak, D. Stewart, and H.P. Koeffler Differentiation therapy of leukemia: 3 decades of development Blood 113 April (16) 2009 3655 3665
25. H.P. Koeffler, and D.W. Golde Human myeloid leukemia cell lines: a review Blood 56 September (3) 1980 344 350 (Pubitemid 11251010)
26. S. Boehrer, L. Ads, L. Galluzzi, N. Tajeddine, M. Tailler, and C. Gardin Erlotinib and gefitinib for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a preclinical comparison Biochem Pharmacol 76 December (11) 2008 1417 1425
27. F. Ravandi, J.E. Cortes, D. Jones, S. Faderl, G. Garcia-Manero, and M.Y. Konopleva Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia J Clin Oncol 28 April (11) 2010 1856 1862
28. E. Buchdunger, C.L. Cioffi, N. Law, D. Stover, S. Ohno-Jones, and B.J. Druker Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors J Pharmacol Exp Ther 295 2000 139 145
29. M. Lindauer, and A. Hochhaus Dasatinib Recent Results Cancer Res 184 2010 83 102
30. L. Han, J.J. Schuringa, A. Mulder, and E. Vellenga Dasatinib impairs long-term expansion of leukemic progenitors in a subset of acute myeloid leukemia cases Ann Hematol 89 September (9) 2010 861 871
31. P.L. Kropf, L. Wang, Y. Zang, R.L. Redner, and D.E. Johnson Dasatinib promotes ATRA-induced differentiation of AML cells Leukemia 24 2010 663 665
32. N. Chevalier, M.L. Solari, H. Becker, M. Pantic, F. Gärtner, and A. Maul-Pavicic Robust in vivo differentiation of t(8;21)-positive acute myeloid leukemia blasts to neutrophilic granulocytes induced by treatment with dasatinib Leukemia 24 October (10) 2010 1779 1781
33. Y. Matsuo, R.A. MacLeod, C.C. Uphoff, H.G. Drexler, C. Nishizaki, and Y. Katayama Two acute monocytic leukemia (AML-M5a) cell lines (MOLM-13 and MOLM-14) with interclonal phenotypic heterogeneity showing MLL-AF9 fusion resulting from an occult chromosome insertion, ins(11;9)(q23;p22p23) Leukemia 11 September (9) 1997 1469 1477 (Pubitemid 27404387)